Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease

Funding represents the first time the foundation has taken an equity position in a breath diagnostics company.

Expanded Treatment Options for Primary Biliary Cholangitis Leave Open Questions

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in management of the condition, substantially reducing

December 1, 2024

Larimar resumes nomlabofusp programme after FDA lifts partial hold – Pharmaceutical Technology

The FDA lifted the partial clinical hold after reviewing Phase II dose escalation data. Image credit: Shutterstock/ Ismail Rajo. Larimar Therapeutics’ clinical programme investigating nomlabofusp

May 21, 2024

Prolonged inactivity affects cholesteryl esters differently depending on age

A new study examining cholesteryl esters suggests that periods of prolonged inactivity may affect people differently depending on their age.

March 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.